A Phase 3, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Chronic lymphocytic leukemia (CLL) is the most common adult leukemia. Although newer treatments have helped many patients, some people experience relapsed disease, meaning the cancer returns after treatment, or refractory disease, meaning the cancer does not respond to treatment. Small lymphocytic lymphoma (SLL) is a similar disease to CLL, but appears mainly in the lymph nodes rather than the blood. BGB-16673 is an investigational drug, meaning it is not approved by the United States Food and Drug Administration (FDA). It is described as selective, meaning it is designed to act mainly on one specific target in the body, in this case a protein called Bruton’s tyrosine kinase (BTK) that helps certain cancer cells survive. This study will compare BGB-16673 used alone (monotherapy) with pirtobrutinib in patients with relapsed or refractory CLL/SLL who have previously received other types of BTK-blocking treatments.

Are you Eligible? (Inclusion Criteria)

• - older than 18 years of age - confirmed diagnosis of CLL or SLL, requiring treatment - must have previously received treatment for CLL/SLL